Fortress Biotech (FBIO) News Today $1.72 -0.02 (-0.86%) Closing price 05/7/2025 03:58 PM EasternExtended Trading$1.75 +0.02 (+1.39%) As of 05/7/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FBIO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025May 7 at 4:01 PM | globenewswire.comFortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual ConferenceMay 7 at 8:00 AM | globenewswire.comThis Fortress Biotech Insider Increased Their Holding By 26% Last YearApril 9, 2025 | finance.yahoo.comJourney Medical Corporation Appoints Ramsey Alloush as Chief Operating OfficerApril 1, 2025 | globenewswire.comFortress Biotech Reports 2024 Financial Results and Recent Corporate HighlightsMarch 31, 2025 | globenewswire.comCheckpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate UpdatesMarch 28, 2025 | globenewswire.comFortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call TranscriptMarch 26, 2025 | seekingalpha.comJourney Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate HighlightsMarch 26, 2025 | globenewswire.comFortress Biotech FY 2024 Earnings PreviewMarch 25, 2025 | msn.comJourney Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of RosaceaMarch 24, 2025 | globenewswire.comJourney Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025March 19, 2025 | globenewswire.comPartex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI PlatformMarch 17, 2025 | globenewswire.comJourney Medical Corporation to Participate in the 37th Annual ROTH ConferenceMarch 12, 2025 | globenewswire.comJulie & Holleman LLP: CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun PharmaMarch 11, 2025 | finanznachrichten.deFortress Biotech price target raised to $16 from $15 at Roth MKMMarch 11, 2025 | markets.businessinsider.comRoth MKM Remains a Buy on Fortress Biotech (FBIO)March 11, 2025 | markets.businessinsider.comCKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun PharmaMarch 10, 2025 | prnewswire.comSun Pharma to Acquire Checkpoint TherapeuticsMarch 9, 2025 | prnewswire.comMustang Bio Regains Compliance with Nasdaq Capital Market RequirementMarch 5, 2025 | globenewswire.comJourney Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat RosaceaMarch 5, 2025 | globenewswire.comJourney Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, FloridaMarch 4, 2025 | globenewswire.comMustang Bio sets terms for $8M public offeringFebruary 6, 2025 | msn.comFortress Biotech announces first patient dosed in Phase 2 trial of TriplexJanuary 27, 2025 | markets.businessinsider.comFortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCTJanuary 27, 2025 | globenewswire.comJourney Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of RosaceaJanuary 23, 2025 | globenewswire.comShort Interest in Fortress Biotech, Inc. (NASDAQ:FBIO) Expands By 9.3%Fortress Biotech, Inc. (NASDAQ:FBIO - Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 3,400,000 shares, a growth of 9.3% from the December 15th total of 3,110,000 shares. Currently, 17.2% of the shares of the company are sold short. Based on an average daily volume of 653,000 shares, the days-to-cover ratio is currently 5.2 days.January 18, 2025 | marketbeat.comFDA extends review of Fortress Biotech's CUTX-101 drugJanuary 16, 2025 | msn.comFortress, Cyprium announce FDA acceptance, priority review of NDA for CUTX-101January 7, 2025 | markets.businessinsider.comFortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes DiseaseJanuary 6, 2025 | globenewswire.comSentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes DiseaseJanuary 6, 2025 | prnewswire.comFortress Biotech (NASDAQ:FBIO) Stock Price Passes Above 200-Day Moving Average - What's Next?Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving Average - Should You Sell?January 1, 2025 | marketbeat.comFortress Biotech, Inc. Common Stock (FBIO) Analyst ResearchDecember 23, 2024 | nasdaq.comCheckpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)December 13, 2024 | globenewswire.comFortress Biotech price target raised to $15 from $13 at Roth MKMNovember 20, 2024 | markets.businessinsider.comFortress Biotech price target raised to $26 from $24 at H.C. WainwrightNovember 18, 2024 | markets.businessinsider.comFortress Biotech price target lowered to $4 from $5 at Alliance Global PartnersNovember 18, 2024 | markets.businessinsider.comFortress Biotech’s Q3 2024 Earnings and FDA MilestoneNovember 15, 2024 | markets.businessinsider.comFortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsNovember 14, 2024 | globenewswire.comCheckpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate UpdatesNovember 12, 2024 | globenewswire.comJourney Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsNovember 12, 2024 | globenewswire.comJourney Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of RosaceaNovember 4, 2024 | globenewswire.comHighbridge Capital Management's Strategic Acquisition of Fortress Biotech SharesOctober 25, 2024 | uk.finance.yahoo.comJourney Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology ConferenceOctober 25, 2024 | globenewswire.comJourney Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceOctober 3, 2024 | globenewswire.comFortress Biotech to Participate in October 2024 Investor ConferencesSeptember 26, 2024 | globenewswire.comLindsay A. Md Rosenwald Buys 763,359 Shares of Fortress Biotech, Inc. (NASDAQ:FBIO) StockSeptember 26, 2024 | insidertrades.comFortress Biotech secures $8 million in stock salesSeptember 22, 2024 | investing.comWhy Fortress Biotech (FBIO) Stock Is Getting HammeredSeptember 20, 2024 | msn.comFortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private PlacementsSeptember 20, 2024 | globenewswire.comCheckpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024September 16, 2024 | globenewswire.com Get Fortress Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address FBIO Media Mentions By Week FBIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FBIO News Sentiment▼0.000.64▲Average Medical News Sentiment FBIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FBIO Articles This Week▼21▲FBIO Articles Average Week Get Fortress Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CDXS News LXRX News SGMO News IRWD News ACHV News AGEN News DOMH News CRIS News SABS News BOLT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FBIO) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersTrump to redistribute trillions of dollars Seeing how the media and other analysts are covering Trump’s actions – it’s laughable. At least it would be la...Porter & Company | Sponsored270x more lucrative than NVIDIA???270x more lucrative than NVIDIA??? If you've missed out on NVIDIA's recent 1,600% run... Don't worry. ...Behind the Markets | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredVanishing BenefitsWhat would you do if your next Social Security check simply never arrived? If you called and the line was d...Investors Alley | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredUrgent News from my Oceanfront Estate Near Mar-a-LagoFor 40 years, I've had a front-row seat to history's greatest wealth creation events. I spotted Microsoft a...InvestorPlace | SponsoredElon’s Been UpgradedThe New Elon Musk is officially stepping back from his day-to-day duties with DOGE. At least, that's the s...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fortress Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fortress Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FBIO Stock Free FBIO Stock Alerts